Periotherapia Raises 575 Million Yen in Series D2 Round
NQ Score
0/100
N1 Content Completeness
9
Key facts
- Periotherapia Raises 575 Million Yen in Series D2 Round
- Periotherapia Co., Ltd. has raised a total of 575 million yen in a Series D2 round. Combined with a maximum subsidy of 1.08 billion yen from AMED, the company has secured over 1.6 billion yen in total funds. The funds will be used to advance clinical trials for its antibody drug PT0101 targeting breast cancer and to expand its pipeline.
- Source: PR TIMES
- Date: Tue Jun 02 2026 19:00:55 GMT+0900 (Japan Standard Time)
Direct answer
Periotherapia Co., Ltd. has raised a total of 575 million yen in a Series D2 round. Combined with a maximum subsidy of 1.08 billion yen from AMED, the company has secured over 1.6 billion yen in total funds. The funds will be used to advance clinical trials for its antibody drug PT0101 targeting breast cancer and to expand its pipeline.
- Citation
- Periotherapia Raises 575 Million Yen in Series D2 Round (Tue Jun 02 2026 19:00:55 GMT+0900 (Japan Standard Time)), PR TIMES
- Source
- PR TIMES
- Date
- Tue Jun 02 2026 19:00:55 GMT+0900 (Japan Standard Time)
AI Summary (NQ-processed)
Periotherapia Co., Ltd. has raised a total of 575 million yen in a Series D2 round. Combined with a maximum subsidy of 1.08 billion yen from AMED, the company has secured over 1.6 billion yen in total funds. The funds will be used to advance clinical trials for its antibody drug PT0101 targeting breast cancer and to expand its pipeline.
AI Analysis
Frequently Asked Questions
- Q: What is the amount raised in Periotherapia's Series D2 round?
- A: The total amount is 575 million yen.
- Q: What is the maximum subsidy from AMED?
- A: The maximum subsidy is 1.08 billion yen.
- Q: What are the main uses of the funds?
- A: Advancing PT0101 clinical trials, pipeline expansion, and organizational strengthening.